Idiopathic pulmonary fibrosis (IPF) is a severe progressive and irreversible lung disease. Novel antifibrotic drugs that slow disease progression are now available. However, many issues regarding patient management remain unanswered, such as the choice between available drugs, their use in particular subgroups and clinical situations, time of treatment onset, termination, combination or switch, or nonpharmacologic management. To guide Swiss respiratory physicians in this evolving field still characterized by numerous areas of uncertainty, the Swiss Working Group for interstitial and rare lung diseases of the Swiss Respiratory Society provides a position paper on the diagnosis and treatment of IPF.

Keywords:
Idiopathic pulmonary fibrosis, Nintedanib, Pirfenidone, Pulmonary fibrosis, Interstitial lung disease
1.
Raghu G, et al: An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
2.
Raghu G, et al: An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 2015;192:e3-e19.
3.
Behr J, et al: German guideline for diagnosis and management of idiopathic pulmonary fibrosis (in German). Pneumologie 2013;67:81-111.
4.
Cottin V, et al: French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis. From the National Reference and the Competence centers for rare diseases and the Societe de Pneumologie de Langue Francaise (in French). Rev Mal Respir 2013;30:879-902.
5.
Xaubet A, et al: Review of IPF diagnosis and management recommendations in Europe. Sarcoidosis Vasc Diffuse Lung Dis 2013;30:249-261.
6.
Baumann MH, et al: Management of spontaneous pneumothorax: an American College of Chest Physicians Delphi consensus statement. Chest 2001;119:590-602.
7.
Geiser T: Idiopathic pulmonary fibrosis - a disorder of alveolar wound repair? Swiss Med Wkly 2003;133:405-411.
8.
Funke M, Geiser T: Idiopathic pulmonary fibrosis: the turning point is now! Swiss Med Wkly 2015;145:w14139.
9.
Walsh SL, et al: Relationship between fibroblastic foci profusion and high resolution CT morphology in fibrotic lung disease. BMC Med 2015;13:241.
10.
Kim EJ, et al: Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2010;35:1322-1328.
11.
Morell F, et al: Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study. Lancet Respir Med 2013;1:685-694.
12.
Song JW, et al: Pathologic and radiologic differences between idiopathic and collagen vascular disease-related usual interstitial pneumonia. Chest 2009;136:23-30.
13.
Coultas DB, et al: The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994;150:967-972.
14.
Baumgartner KB, et al: Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1997;155:242-248.
15.
Savarino E, et al: Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. Eur Respir J 2013;42:1322-1331.
16.
Baumgartner KB, et al: Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study. Collaborating Centers. Am J Epidemiol 2000;152:307-315.
17.
Lee JS: The role of gastroesophageal reflux and microaspiration in idiopathic pulmonary fibrosis. Clin Pulm Med 2014;21:81-85.
18.
Molyneaux PL, Maher TM: The role of infection in the pathogenesis of idiopathic pulmonary fibrosis. Eur Respir Rev 2013;22:376-381.
19.
Wolters PJ, Collard HR, Jones KD: Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol 2014;9:157-179.
20.
Lee HL, et al: Familial idiopathic pulmonary fibrosis: clinical features and outcome. Chest 2005;127:2034-2041.
21.
Raghu G, et al: Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-2011. Lancet Respir Med 2014;2:566-572.
22.
Nalysnyk L, et al: Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev 2012;21:355-361.
23.
Karakatsani A, et al: Epidemiology of interstitial lung diseases in Greece. Respir Med 2009;103:1122-1129.
24.
Rudd RM, et al: British Thoracic Society Study on cryptogenic fibrosing alveolitis: response to treatment and survival. Thorax 2007;62:62-66.
25.
Collard HR, et al: Acute exacerbation of idiopathic pulmonary fibrosis. An International Working Group report. Am J Respir Crit Care Med 2016;194:265-275.
26.
Collard HR, et al: Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007;176:636-643.
27.
Ryerson CJ, et al: Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm. Eur Respir J 2015;46:512-520.
28.
Peljto AL, et al: Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA 2013;309:2232-2239.
29.
Noth I, et al: Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med 2013;1:309-317.
30.
Ley B, Brown KK, Collard HR: Molecular biomarkers in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2014;307:L681-L691.
31.
Ley B, et al: A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012;156:684-691.
32.
Bahmer T, et al: The use of auto-antibody testing in the evaluation of interstitial lung disease (ILD) - a practical approach for the pulmonologist. Respir Med 2016;113:80-92.
33.
Fischer A, et al: An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 2015;46:976-987.
34.
Meyer KC, et al: An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 2012;185:1004-1014.
35.
Welker L, et al: Predictive value of BAL cell differentials in the diagnosis of interstitial lung diseases. Eur Respir J 2004;24:1000-1006.
36.
Casoni GL, et al: Transbronchial lung cryobiopsy in the diagnosis of fibrotic interstitial lung diseases. PLoS One 2014;9:e86716.
37.
Tomassetti S, et al: Bronchoscopic lung cryobiopsy increases diagnostic confidence in the multidisciplinary diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2016;193:745-752.
38.
Johannson KA, et al: Diagnostic yield and complications of transbronchial lung cryobiopsy for interstitial lung disease. A systematic review and metaanalysis. Ann Am Thorac Soc 2016;13:1828-1838.
39.
Travis WD, et al: An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013;188:733-748.
40.
Walsh SL, et al: Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study. Lancet Respir Med 2016;4:557-565.
41.
Walsh SL, et al: Interobserver agreement for the ATS/ERS/JRS/ALAT criteria for a UIP pattern on CT. Thorax 2016;71:45-51.
42.
Oldham JM, et al: TOLLIP, MUC5B and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2015;192:1475-1482.
43.
Raghu G, et al: Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J 2015;46:1113-1130.
44.
Fulton BG, Ryerson CJ: Managing comorbidities in idiopathic pulmonary fibrosis. Int J Gen Med 2015;8:309-318.
45.
Seeger W, et al: Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 2013;62(suppl):D109-D116.
46.
Lancaster LH, et al: Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest 2009;136:772-778.
47.
Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, et al: Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012;366:1968-1977.
48.
Conte E, et al: Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur J Pharm Sci 2014;58:13-19.
49.
Noble PW, et al: Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377:1760-1769.
50.
King TE Jr, et al: A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2083-2092.
51.
Valeyre D, et al: Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology 2014;19:740-747.
52.
King CS, Nathan SD: Practical considerations in the pharmacologic treatment of idiopathic pulmonary fibrosis. Curr Opin Pulm Med 2015;21:479-489.
53.
Borie R, et al: Pharmacological management of IPF. Respirology 2016;21:615-625.
54.
Wollin L, et al: Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 2015;45:1434-1445.
55.
Hostettler KE, et al: Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Respir Res 2014;15:157.
56.
Richeldi L, et al: Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2071-2082.
57.
Richeldi L, et al: Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS® trials. Respir Med 2016;113:74-79.
58.
Rochwerg B, et al: Treatment of idiopathic pulmonary fibrosis: a network meta-analysis. BMC Med 2016;14:18.
59.
Canestaro WJ, et al: Drug treatment of idiopathic pulmonary fibrosis: systematic review and network meta-analysis. Chest 2016;149:756-766.
60.
Costabel U, et al: Efficacy of nintedanib in idiopathic pulmonary fibrosis across pre-specified subgroups in INPULSIS®. Am J Respir Crit Care Med 2016;193:178-185.
61.
Harari S, et al: Efficacy of pirfenidone for idiopathic pulmonary fibrosis: an Italian real life study. Respir Med 2015;109:904-913.
62.
Raghu G, et al: Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria. Am J Respir Crit Care Med 2017;195:78-85.
63.
Moodley Y, et al: Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective. Respirology 2015;20:389-394.
64.
Loeh B, et al: Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2015;191:110-113.
65.
Wuyts WA, et al: First data on efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis and forced vital capacity of ≤50% of predicted value. Lung 2016;194:739-743.
66.
Wiggins J, Strickland B, Turner-Warwick M: Combined cryptogenic fibrosing alveolitis and emphysema: the value of high resolution computed tomography in assessment. Respir Med 1990;84:365-369.
67.
Wells AU, et al: Lone cryptogenic fibrosing alveolitis: a functional-morphologic correlation based on extent of disease on thin-section computed tomography. Am J Respir Crit Care Med 1997;155:1367-1375.
68.
Doherty MJ, et al: Cryptogenic fibrosing alveolitis with preserved lung volumes. Thorax 1997;52:998-1002.
69.
Mejia M, et al: Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest 2009;136:10-15.
70.
Akagi T, et al: Coexistent emphysema delays the decrease of vital capacity in idiopathic pulmonary fibrosis. Respir Med 2009;103:1209-1215.
71.
Ryerson CJ, et al: Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest 2013;144:234-240.
72.
Kohashi Y, et al: Clinical impact of emphysema evaluated by high-resolution computed tomography on idiopathic pulmonary fibrosis diagnosed by surgical lung biopsy. Respiration 2016;92:220-228.
73.
Cottin V, et al: Combined pulmonary fibrosis and emphysema (in French). Presse Med 2007;36(pt 2):936-944.
74.
Lancaster L, et al: Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials. BMJ Open Respir Res 2016;3:e000105.
75.
Nathan SD, et al: Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax 2016;71:429-435.
76.
Milger K, et al: Switching to nintedanib after discontinuation of pirfenidone due to adverse events in IPF. Eur Respir J 2015;46:1217-1221.
77.
Ogura T, et al: Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2015;45:1382-1392.
78.
Idiopathic Pulmonary Fibrosis Clinical Research Network, Martinez FJ, et al: Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2093-2101.
79.
Behr J, et al: Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med 2016;4:445-453.
80.
Weill D, et al: A consensus document for the selection of lung transplant candidates: 2014 - an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2015;34:1-15.
81.
Brown AW, Kaya H, Nathan SD: Lung transplantation in IIP: a review. Respirology 2016;21:1173-1184.
83.
Kenn K, Gloeckl R, Behr J: Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis - a review. Respiration 2013;86:89-99.
84.
Bahmer T, et al: Clinical correlates of reduced physical activity in idiopathic pulmonary fibrosis. Respiration 2016;91:497-502.
85.
Frank RC, et al: Ambulatory oxygen in idiopathic pulmonary fibrosis: of what benefit? Eur Respir J 2012;40:269-270.
86.
Bräunlich J, et al: Effects of nasal high flow on ventilation in volunteers, COPD and idiopathic pulmonary fibrosis patients. Respiration 2013;85:319-325.
87.
Blivet S, et al: Outcome of patients with idiopathic pulmonary fibrosis admitted to the ICU for respiratory failure. Chest 2001;120:209-212.
88.
Rush B, et al: The use of mechanical ventilation in patients with idiopathic pulmonary fibrosis in the United States: a nationwide retrospective cohort analysis. Respir Med 2016;111:72-76.
89.
Yokoyama T, et al: Noninvasive ventilation in acute exacerbation of idiopathic pulmonary fibrosis. Intern Med 2010;49:1509-1514.
90.
Vianello A, et al: Noninvasive ventilation in the event of acute respiratory failure in patients with idiopathic pulmonary fibrosis. J Crit Care 2014;29:562-567.
91.
Lindell KO, et al: Palliative care and location of death in decedents with idiopathic pulmonary fibrosis. Chest 2015;147:423-429.
92.
Ahmadi Z, et al: End-of-life care in oxygen-dependent ILD compared with lung cancer: a national population-based study. Thorax 2016;71:510-516.
93.
Antoniou KM, Wells AU: Acute exacerbations of idiopathic pulmonary fibrosis. Respiration 2013;86:265-274.
94.
Papiris SA, et al: Survival in Idiopathic pulmonary fibrosis acute exacerbations: the non-steroid approach. BMC Pulm Med 2015;15:162.
95.
Raghu G, et al: Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction. Eur Respir J 2015;46:1370-1377.
96.
Bayer Corporation: Bayer terminates phase II study with riociguat in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias. 2016. http://www.prnewswire.com/news-releases/bayer-terminates-phase-ii-study-with-riociguat-in-patients-with-pulmonary-hypertension-associated-with-idiopathic-interstitial-pneumonias-300267616.html.
97.
Funke M, Geiser T, Schoch OD: Pulmonary hypertension associated with chronic lung diseases. Swiss Med Wkly 2016;146:w14363.
98.
Kreuter M, et al: Screening for Helicobacter pylori in idiopathic pulmonary fibrosis lung biopsies. Respiration 2016;91:3-8.
99.
Ghebre YT, Raghu G: Idiopathic pulmonary fibrosis: novel concepts of proton pump inhibitors as antifibrotic drugs. Am J Respir Crit Care Med 2016;193:1345-1352.
100.
Lee JS, et al: Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med 2013;1:369-376.
101.
Kreuter M, et al: Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respir Med 2016;4:381-389.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.